DAMN THIS SNAP VAN YOU TRICKED ME!!! YOU SAID $70+ WHAT'S THIS CHANGE OF HEART!
-LONG TIME AGO SEPT/////
Ascendiant starts Atossa Therapeutics with Buy rating, $7 price target 09/17/20 ATOS Ascendiant analyst Edward Woo initiated coverage of Atossa Therapeutics with a Buy rating and $7 price target. The company has two COVID-19 drugs under development: AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation, and AT-301, a nasal spray for COVID-19 patients who are not sufficiently ill to require hospitalization, Woo tells investors in a research note. Further, Atossa's breast cancer drug under development is its proprietary form of Endoxifen, adds the analyst. Woo sees large market potential for Atossa Therapeutics.
-LONG TIME AGO SEPT/////
Ascendiant starts Atossa Therapeutics with Buy rating, $7 price target 09/17/20 ATOS Ascendiant analyst Edward Woo initiated coverage of Atossa Therapeutics with a Buy rating and $7 price target. The company has two COVID-19 drugs under development: AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation, and AT-301, a nasal spray for COVID-19 patients who are not sufficiently ill to require hospitalization, Woo tells investors in a research note. Further, Atossa's breast cancer drug under development is its proprietary form of Endoxifen, adds the analyst. Woo sees large market potential for Atossa Therapeutics.